Recruiting

Ketorolac

Sponsor:

Jessica D. Kresowik

Code:

NCT07185724

Conditions

Infertility (IVF Patients)

Infertility Treatment

Post-op Pain

Fresh Embryo Transfer

Oocyte Retrieval and Post Operative Pain Control

Eligibility Criteria

Sex: Female

Age: 18 - 37

Healthy Volunteers: Not accepted

Interventions

Ketorolac 30 mg IV

Study Details

Brief summary:

Ketorolac is a medication often used to relieve pain after surgery. In the past, infertility doctors have been cautious about using ketorolac after egg retrieval for patients planning a fresh embryo transfer (usually done 5 days later). The concern was that ketorolac might increase the risk of bleeding or reduce the chances of the embryo implanting in the uterus. This concern comes from how ketorolac works-it blocks certain chemicals in the body (like prostaglandins and thromboxane) that help with blood clotting and play a role in early pregnancy.

However, a large review of past studies found no real evidence that ketorolac increases bleeding risk. In fact, ketorolac is now routinely used for pain relief in IVF cycles where embryos are frozen and not transferred right away. More recent studies from Boston and Chapel Hill have shown that ketorolac provides better pain control and does not appear to harm IVF outcomes, even when embryos are transferred fresh (within the same cycle).

Despite these encouraging findings, many IVF clinics still avoid using ketorolac during fresh cycles because of the theoretical concerns. That's why we need stronger, higher-quality research.

This study aims to fill that gap by conducting a double-blind randomized controlled trial to find out whether giving ketorolac through an IV after egg retrieval affects important IVF outcomes-especially the chance of implantation and live birth-in patients undergoing fresh embryo transfers. Patients who choose to join the study will randomly be placed into one of two groups. One group will get ketorolac (a pain medicine) after an IVF egg retrieval. The other group will not get ketorolac after egg retrieval. Everything else in their IVF care will stay the same as it normally would.

Primary outcome will be implantation rate following fresh embryo transfers in patients receiving ketorolac (30mg IV) vs no ketorolac for post-retrieval analgesia.

Secondary outcomes will include pain scale, narcotics required, time to discharge, need for evaluation w/in 24 hours for pain/bleeding, clinical pregnancy rates, miscarriage rates, and live birth rates following fresh embryo transfers in patients receiving ketorolac vs no ketorolac for post-retrieval analgesia.

Conditions

Infertility (IVF Patients)

Infertility Treatment

Post-op Pain

Fresh Embryo Transfer

Oocyte Retrieval and Post Operative Pain Control

Study ID

NCT07185724

Start date

Nov 8, 2025

Status verified date

Dec, 2025

Completion date

Sep 1, 2028

Anticipated

Primary completion date

Oct 1, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Female

Age: 18 - 37

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • IVF utilizing autologous oocytes and all sperm sources
  • IVF cycles utilizing ICSI and standard insemination
  • Plan to transfer embryo on day 5
  • BMI below 50

Exclusion Criteria:

-allergies or medical contraindications to NSAIDs

Study Design

Enrollment

200 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: IV Ketorolac

Participants randomized to this arm will receive 30mg IV Ketorolac at the conclusion of their oocyte retrieval.

no intervention: No IV Ketorolac

Participants randomized to this arm will not receive IV Ketorolac at the conclusion of their oocyte retrieval.

Interventions

Ketorolac 30 mg IV

We will be evaluating the effect of post-oocyte retrieval ketorolac administration on clinical outcomes in fresh embryo transfer cycles.

Primary outcome measure

  • Implantation Rate [ Time Frame: From enrollment to the time of confirmation of pregnancy ultrasound at ~6 weeks post-oocyte retrieval (with or without administration of IV Ketorolac) . ]

Central Contacts and Locations

Central contacts

Locations

UI Health Care Center for Advanced Reproductive Care

Recruiting

Iowa City, Iowa, United States, 52245

Contacts

Principal Investigator:

Jessica Kresowik

More Information

Sponsor

Jessica D. Kresowik

Last update posted

Dec 15, 2025

Last verified

Dec, 2025

Keywords

  • IVF
  • post operative pain control
  • oocyte retrieval
  • fresh embryo transfer
  • ketorolac
  • toradol
  • implantation rate
  • live birth rate
  • miscarriage rate

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Jessica D. Kresowik on 2025-12-15.